Mylan May Be the First to File Complete ANDA with Paragraph IV Certification for Copaxone 40
Mylan believes that it may be the first generic pharmaceutical company to file a complete ANDA with paragraph IV certification for Teva’s Copaxone 40.
Copaxone 40 mg litigations On August 24, 2016, Mylan (MYL) announced that the PTO (US Patent and Trademark Office) invalidated patents 8,232,250 and 8,399,413, which are related to Teva Pharmaceutical…
In a Bloomberg survey of 19 brokerage companies on August 25, 2016, about 89.5% of analysts rated Thermo Fisher Scientific as a “buy,” and 10.5% rated it as a “hold.”
After the release of its 2Q16 earnings results on July 28, 2016, Thermo Fisher Scientific (TMO) was trading at a forward PE (price-to-earnings) multiple of 17.9x–18.5x.
Thermo Fisher Scientific believes that the FEI acquisition is a strategic fit for the company due to its strong product portfolio.
Thermo Fisher Scientific reported ~$4.5 billion in revenues in 2Q16, representing YoY (year-over-year) growth of ~6%.
According to a Bloomberg consensus of 19 brokerage firms as of August 23, 2016, 94.7% of analysts recommend a “buy” for BioMarin stock.
Wall Street analysts project that Kuvan will earn $351.2 million and $389.4 million in 2016 and 2017, respectively.
Vimizim is BioMarin’s (BMRN) lead drug. It earned $179.4 million in the first six months of 2016, which is a 71.7% increase over the first half of 2015.
During its 2Q16 earnings call, BioMarin revised its 2016 revenue guidance. It now expects revenue to be $1.1 billion–$1.15 billion.
With increased M&A activity in the pharmaceuticals and biotechnology space, it wouldn’t be surprising if Roche Holding (RHHBY) acquired BioMarin (BMRN).
BioMarin’s premium valuation over its peers follows its robust and promising pipeline. Rumored interest by Roche caused a recent spurt in its valuation multiple.
On August 18, 2016, Illumina (ILMN) rose more than 3% amid rumors of Thermo Fisher Scientific (TMO) acquiring Illumina for $30 billion in an all-stock deal.
After the release of its 2Q16 earnings results on July 21, 2016, Stryker (SYK) was trading at a forward PE (price-to-earnings) multiple of 18.6x–19.1x.
Stryker (SYK) expects its 2016 revenue to witness a YoY (year-over-year) rise of 6%–6.5% on an organic basis.
Stryker (SYK) has always expanded actively through mergers and acquisitions and continues to follow the same growth strategy.
Europe represents a potential growth opportunity for Stryker, as the company currently has a low market share in Europe compared to other developed markets.
Stryker registered ~$2.8 billion in revenue in 2Q16. Around 72% of this was generated by its US business, and the remainder came from international sales.
Stryker constantly aims to develop new products and enhance its existing products through internal R&D (research and development).
Stryker (SYK) entered the robot-assisted surgery market with its acquisition of MAKO Surgical in December 2013.